Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan in PAH associated with Sickle Cell Disease (ASSET-1)
NCT00310830Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2006
- Primary completion
- Aug 2007
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
01
Overview
A Phase 3 trial of bosentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Mar 2006; status: terminated.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00310830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00310830.